Download presentation
Presentation is loading. Please wait.
1
Treating HIV Infection:
2
HIV/AIDS Treatment A Dynamic Field
3
SINGLE Study Phase 3, Open-Label Extension Results, Weeks 96 to 144
4
Dolutegravir Clinical Trials Phase 3 Open-Label Extension Results, Weeks 96 to 144 (cont)
5
Pharmacoenhancers What's New?
6
COBI* vs RTV as a Pharmacoenhancer for TDF/FTC Efficacy Results at 144 Weeks
7
COBI vs RTV as a Pharmacoenhancer for TDF/FTC Safety Results at 144 Weeksa (cont)
8
COBI vs RTV as a Pharmacoenhancer for TDF/FTC Safety Results at 144 Weeks (cont)
9
Low Bone Mineral Density An Age- and ART-Related Comorbidity in People With HIV Infection
10
TAF: A Novel Tenofovir Prodrug Phase 2: DRV/cobi + TAF/FTC vs DRV/cobi + TDF/FTC: Efficacy
11
DRV/cobi + TAF/FTC vs DRV/cobi + TDF/FTC BMD Changes
12
DRV/r + RAL vs TDF/FTC Effect on BMD at 96 Weeks
13
Renal Markers More Favorable for TAF Compared With TDF Renal Function at 48 Weeks
14
Cabotegravir Injectable Long-acting Integrase Strand Transfer Inhibitors Dose-finding Study
15
Abbreviations
16
Abbreviations (cont)
17
References
18
References (cont)
19
References (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.